You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Effect of modafinil on impulsivity and relapse in alcohol dependent patients: A randomized, placebo-controlled trial
|
|---|---|
| Published in |
European Neuropsychopharmacology, November 2012
|
| DOI | 10.1016/j.euroneuro.2012.10.004 |
| Pubmed ID | |
| Authors |
Leen Joos, Anna E. Goudriaan, Lianne Schmaal, Erik Fransen, Wim van den Brink, Bernard G.C. Sabbe, Geert Dom |
| Abstract |
Poor impulse control plays an important role in the development, course and relapse of substance use disorders. Therefore, improving impulse control may represent a promising approach in the treatment of alcohol dependence. This study aimed to test the effect of modafinil on impulse control and alcohol use in alcohol dependent patients (ADP) in a randomized, double-blind, placebo-controlled trial. Eighty-three abstinent ADP were randomized to 10 weeks modafinil (300 mg/d) or placebo. Alcohol use was quantified using the timeline follow-back method and was assessed until 6 months after treatment discontinuation. Impulsivity was assessed using self-report questionnaires (Barratt Impulsiveness Scale; State Impulsivity questionnaire) and neurocognitive tasks (Stop Signal Task; Delay Discounting Task) administered before, during and after treatment. Modafinil significantly improved self-report measures of state impulsivity, but had no effect on percentage of abstinent days or percentage of heavy drinking days, nor on the behavioral measures of impulsivity. However, subgroup analysis revealed that modafinil prolonged the time to relapse (p=.022) and tended to increase the percentage of abstinent days (p=.066) in ADP with poor response inhibition at baseline, whereas modafinil increased the percentage of heavy drinking days (p=.003) and reduced the percentage of abstinent days (p=.002) in patients with better baseline response inhibition. Overall results do not favor the use of modafinil in order to reduce relapse or relapse severity in ADP, and caution is required in prescribing modafinil to a non-selected sample of ADP. Further research on the effect of modafinil in ADP with poor baseline response inhibition is warranted. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 110 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | <1% |
| France | 1 | <1% |
| Australia | 1 | <1% |
| Canada | 1 | <1% |
| Romania | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 104 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 16 | 15% |
| Student > Bachelor | 16 | 15% |
| Student > Ph. D. Student | 15 | 14% |
| Student > Master | 14 | 13% |
| Student > Doctoral Student | 10 | 9% |
| Other | 18 | 16% |
| Unknown | 21 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Psychology | 31 | 28% |
| Medicine and Dentistry | 21 | 19% |
| Agricultural and Biological Sciences | 6 | 5% |
| Social Sciences | 5 | 5% |
| Neuroscience | 4 | 4% |
| Other | 12 | 11% |
| Unknown | 31 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 September 2013.
All research outputs
#16,721,717
of 25,374,647 outputs
Outputs from European Neuropsychopharmacology
#1,414
of 2,571 outputs
Outputs of similar age
#125,527
of 198,390 outputs
Outputs of similar age from European Neuropsychopharmacology
#11
of 23 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,571 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one is in the 42nd percentile – i.e., 42% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 198,390 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 34th percentile – i.e., 34% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.